EpicentRx is a patient-driven immuno-oncology company with minimally toxic therapies that work across diverse patient populations and tumor types for the best possible quality of life during treatment. Through two complementary technology platforms that each activate and mobilize a different half of the immune system, innate (non-specific) and adaptive (specific) immunity, the company is developing drug candidates that are specifically toxic to tumor cells, not normal cells. EpicentRx’s lead program, RRx-001, has been tested in several clinical trials, including an ongoing Phase 3 study in small cell lung cancer. It is among a portfolio of small molecule compounds that favorably alter the tumor microenvironment and activate tumor associated macrophages (TAMs) of the innate immune response. The company is also advancing multiple programs through its smart virus platform, including personalized cancer vaccines that have been shown to eradicate tumors and prevent them from returning.
Dr. COREY CARTER
President & CEO
LCDR (retired, USN) Corey A. Carter, M.D., a San Diego native and an ex-submariner, is President and CEO of EpicentRx as well as a practicing oncologist with three board certifications in Internal Medicine, Hematology and Oncology. Prior to joining EpicentRx, Dr. Carter served as a Senior Clinical Investigator at the NIH and Chief of Thoracic Oncology at Walter Reed. At Walter Reed, he was the Principal Investigator of over 100 clinical trials including the Phase 2 clinical trial QUADRUPLE THREAT where he was the first Investigator to administer RRx-001. Dr. Carter received his B.S. from University of Washington and his M.D. from Uniform Services University of the Health Sciences, Bethesda, Maryland. With an expertise in cancer immunology and a “patient‐first” focus, his objective—and the reason he left a busy clinical practice for EpicentRx—is to bring about a paradigm shift in the way that all patients are treated so that both quantity and quality of life are preserved. As a veteran of Operation Enduring Freedom in Kandahar, Afghanistan, his credo is: leave no patient behind.
Dr. FRANCK BRINKHAUS
Chief Financial Officer
Dr. Brinkhaus serves as EpicentRx Chief Financial Officer and has experience in strategic advice, corporate finance and capital raising for life science companies. He is CEO & Founder of Biotech Alliances International, Inc., a Silicon Valley-based life sciences investment bank. Previously, Dr. Brinkhaus was Managing Director of Palo Alto-based Woodside Capital Partners. He holds a Master’s degree and a Ph.D. in Economics.
Dr. TONY REID
Chief Scientific Officer
Tony Reid, M.D. Ph.D., Chief Scientific Officer, holds a PhD focused in Antiviral and Antitumor Activity from Stanford. Reid further pursued his MD at Stanford focusing on targeted viral vector for cancer therapy and histone deacetylase inhibitors. In addition to his role at EpicentRx, Reid continues his 13 years as a Professor of Medicine at the University of California San Diego Moores Cancer Center as a medical oncologist focused on early phase clinical research while simultaneously developing an adenoviral platform. Dr. Reid holds numerous national awards such as America’s Top Doctor (top 1%), 2008 to present, America’s Top Doctor for Cancer (top 1%), 2009 to present, and America’s Most Honored Professional (top 1%), 2016, 2017.
Dr. BRYAN ORONSKY
Chief Medical Officer
Dr. Oronsky serves as EpicentRx Chief Medical Officer and combines first hand clinical experience with 15 years of pharmaceutical development experience. Before joining EpicentRx, Dr. Oronsky worked as a Medical Officer at Intarcia Therapeutics. He has published over 100 peer-reviewed scientific articles, reviews and book chapters. He is also co-inventor of 10 issued patients and over 50 pending patents in the biomedical and device fields. Dr. Oronsky was educated at Princeton University, Catholic University in Belgium and University of Miami Medical School
Sarah Hibbard has served as our General Counsel since May 2018. In her role, she oversees all legal matters, including contracts, intellectual property, and corporate governance. From 2012 until 2018, Ms. Hibbard served in-house at Encore Capital Group., where she handled Litigation and Government Affairs.
Dr. CHRIS LARSON
Vice President of Viral Therapy
After completing medical school at UT Southwestern and a research-track hematology/oncology fellowship at UC San Diego, Dr. Larson developed techniques to expand the versatility of the oncolytic viral platform and spearheaded the personalized virus manufacturing program.
Director of Operations & Corporate Development
As Director of Operations & Corporate Development for EpicentRx, Mr. Caroen is highly skilled in Clinical Program Development, Effective Conduct of Clinical Trials, Good Clinical Practices, and Life Science Business Strategies. He is responsible for clinical development of RRx-001 and additionally helps to drive business development by prioritizing opportunities, conducting diligence, and transacting business and collaboration opportunities. Mr. Caroen is a co-author on over 40 peer reviewed scientific publications and co-inventor on 3 pending patents.
Director of Regulatory Affairs
Gina Varner serves as the Director of Regulatory Affairs for EpicentRx, Inc. where she fosters relationships with regulatory agencies, provides regulatory guidance to team members, and oversees general quality and compliance. Prior to joining the EpicentRx team, Ms. Varner held various positions in clinical trials administration and regulatory affairs at the UC San Diego Moores Cancer Center where she led projects to increase efficiency through the implementation of computerized systems. As a cancer survivor, Ms. Varner is passionate about finding new and creative ways to approach personalized drug development. Outside of work, she spends most of her time hiking and camping in the beautiful southern Californian mountains and deserts. Ms. Varner holds a bachelor’s degree in Biology from Point Loma Nazarene University and a Master’s in Public Health from San Diego State University.